HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced the planned acquisition of Dura Medical, under a non-binding Letter of Intent. Dura is expected to be the first Florida acquisition for HOPE and serve as a cornerstone for the Southeastern States. Dura is revenue generating and EBITDA positive with immediate expansion opportunity to Florida’s East Coast and beyond. Stephen Durand, founder of Dura, will serve as Director of Clinic Growth for HOPE in Florida. The acquisition is expected to be immediately accretive to revenue and EBITDA for NRx.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals, Hope announce planned acquisition of Kadima
- NRx Pharmaceuticals announces first section of NDA for NRX-100
- NRX Pharmaceuticals Strengthens Leadership with New CFO Appointment
- NRx Pharmaceuticals Reports Progress in Drug Development
- NRx Pharmaceuticals names Michael Abrams as CFO